Chemomab Therapeutics (NASDAQ:CMMB) and Zenas BioPharma (NASDAQ:ZBIO) Critical Review

Zenas BioPharma (NASDAQ:ZBIO) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.

Earnings and Valuation

This table compares Zenas BioPharma and Chemomab Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$15.00 million	72.14	-$156.99 million	($7.07)	-2.85
Chemomab Therapeutics	N/A	N/A	-$13.94 million	($2.96)	-0.56

Chemomab Therapeutics has lower revenue, but higher earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Zenas BioPharma and Chemomab Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1	1	6	0	2.63
Chemomab Therapeutics	1	1	2	0	2.25

Zenas BioPharma currently has a consensus price target of $43.14, indicating a potential upside of 114.00%. Chemomab Therapeutics has a consensus price target of $26.50, indicating a potential upside of 1,496.39%. Given Chemomab Therapeutics’ higher possible upside, analysts clearly believe Chemomab Therapeutics is more favorable than Zenas BioPharma.

Profitability

This table compares Zenas BioPharma and Chemomab Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-73.55%	-57.60%
Chemomab Therapeutics	N/A	-110.78%	-93.27%

Institutional and Insider Ownership

46.1% of Chemomab Therapeutics shares are owned by institutional investors. 16.5% of Zenas BioPharma shares are owned by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Zenas BioPharma has a beta of -1.45, indicating that its stock price is 245% less volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

About Zenas BioPharma

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.